LearnGlossaryMarketStocksSuperinvestorsSign in

FOLD

Amicus Therapeutics, Inc.

Healthcare · $4.5B market cap

Verdict

We can't put a fair value on FOLD right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-7.9% a year✗
Sales growth20.7% a year✓
Free cash flow growth4.1% a year✗
Return on invested capital-14.5%✗

Follow FOLD

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Apr 27, 2026. How the Payback Price works